Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesCost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease
PharmacoEconomics, 08/19/09
Yu AP et al. – This analysis suggests that adalimumab maintenance therapy is a dominant strategy versus infliximab maintenance therapy for patients with moderate to severe Crohn's disease. Adalimumab appeared more effective and less costly than infliximab.
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. A Cost-Effectiveness Analysis
Annals of Internal Medicine, 11/03/09
Societal cost of rheumatoid arthritis patients in the US
Current Medical Research and Opinion, 11/13/09
Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation
Current Medical Research and Opinion, 11/13/09
Today in Stomach/GI...keeping you current
Receive free subspecialty "5-minute updates" via email
Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09
Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin
Journal of Viral Hepatitis, 11/09/09
Proton Pump Inhibitors and Pain
Pain Physician, 11/25/09
Sponsor
Article Search
Sponsor